MedTrace Logo

Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure

NCT05885607 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-02-13

No results posted yet for this study

Summary

The goal of this observational study is to learn about SGLT2 inhibition medications in patients with symptomatic heart failure who are clinically prescribed FDA-approved SGLT2 inhibitors. The main question it aims to answer is:

* What are the impacts of SGLT2 inhibition on systemic metabolomic and proteomic profiles? Participants will be asked to do the following before and after being prescribed a SGLT2i.
* Six-minute walk testd
* Calf MRI with plantar flexion exercise
* Blood sample collection

Conditions

  • Heart Failure NYHA Class II
  • Heart Failure NYHA Class III
  • Heart Failure

Sponsors & Collaborators

Principal Investigators

  • Kenneth Margulies, MD · University of Pennsylvania

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-27
Primary Completion
2026-02-09
Completion
2026-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05885607 on ClinicalTrials.gov